This mechanistic exploration combining genetic knockdown and pharmacological approaches establishes LXRβ’s critical role in depression pathogenesis, providing an experimental foundation for developing LXR-targeted therapeutic strategies [38]. This evidence concerns the gene NR1H2 and major depressive disorder.